Protalix BioTherapeutics Financials - Benzinga

Protalix BioTherapeutics Inc

PLXAMEX

Trade with Public

Trade with Public

$2.22

-0.14-5.93%

At close: Aug 14, 5:00 PM EST

Earnings: Q2 2026 Earnings were released on Wed Aug 12th, before the market open

Conference Call: The most recent conference call started at 8:00 AM, 4 days ago

Click to view the webcast

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Protalix BioTherapeutics Financials

Protalix BioTherapeutics (PLX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Protalix BioTherapeutics Q2 EPS $0.05 Misses $0.12 Estimate, Sales $19.896M Beat $12.931M Estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.12 by 58.33 percent. The company reported quarterly sales of $19.896 million which

Benzinga Newsdesk

PRO
CORRECTION: Protalix BioTherapeutics Q1 EPS $0.22 Beats $0.06 Estimate, Sales $33.750M Beat $11.468M Estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.06 by 266.67 percent. This is a 540 percent increase over losses of $(0.05) per share

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

Earnings Scheduled For March 18, 2026

Benzinga Insights

PRO
Protalix BioTherapeutics Expects FY26 Total Revenue To Range From ~$78M To $83M Including $25M Milestone Which Protalix Is Entitled To From Chiesi

Financial Outlook: Building Durable Growth and Long–Term ValueProtalix enters 2026 with a profitable commercial business through its partnerships and a focused pipeline aligned to areas of high unmet need. The

Benzinga Newsdesk

PRO
Protalix BioTherapeutics Q4 EPS $(0.06) Misses $0.04 Estimate, Sales $9.300M Miss $16.918M Estimate

Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.04 by 250 percent. This is a 166.67 percent decrease over earnings of $0.09 per share

Benzinga Newsdesk